Loading data for TLX — first visit, this takes a few seconds.

Telix Pharmaceuticals Limited (TLX)

NasdaqGS: TLX · 即時價格 · USD

12.08

+0.14 (1.17%)

收盤價： Sep 11, 2026, 8:00 PM

11.11

-1.59%

盤後: 7:53 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	12.08
市值	3.84B
營收 (ttm)	891M
淨利（ttm）	33.5M
	0.60
	0.09
	125.44
	77.02
P/B (ttm)	7.87
P/S (ttm)	4.29
財報日期	n/a

賣價	11.46
成交量	224,545
20 日平均成交量	157,201
開盤價	12.05
前收盤價	11.94
當日區間	12.04 - 12.21
52 週範圍	6.28 - 12.48
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 TLX

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with adv...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Nov 14, 2024

員工 1,120

證券交易所 NasdaqGS

股票代號 TLX

網站 https://telixpharma.com

完整的公司簡介

財務表現

Telix Pharmaceuticals 在 2025 年的營收為 803.79M，較前一年的 516.55M 增加 55.61%。淨利為 -7.13M，較前期減少 -121.15%。

財務報表

財報驚奇

Telix Pharmaceuticals 已於 Invalid Date 公布季度財報：

營收為 n/a 低於預期 $0, 年增 NaN% 成長.
每股盈餘為低於預期 , 年增 NaN% 成長.

價格為何變動

新聞動態

1 週前 · Stocktwits

TLX Stock Clocks 5% Gain This Week Ahead Of FDA Decision On Brain Cancer Imaging Agent

The FDA’s target date for deciding on Pixclara is September 11.

1 週前 · MT Newswires

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State

1 週前 · MT Newswires

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th

1 週前 · InvestorsHub

Telix Pharmaceuticals Shares Rise 5.3% as Analyst Highlights BiPASS Trial and FDA Pathway

Telix Pharmaceuticals Ltd ADR (NASDAQ:TLX) shares rose 5. 3% in premarket trading on Wednesday as investors assessed the company’s Phase 3 BiPASS trial progress and its regulatory pathway in the U.

1 週前 · Simply Wall St.

Fast Growing ASX Stocks With High Insider Ownership Worth Watching

Rising treasury and sovereign yields driven by persistent inflation concerns are forcing investors to think harder about where future growth might justify the extra risk. This is where fast-growing st...

第 1 頁，共 2 頁

Telix Pharmaceuticals Limited (TLX)